Strategic Alliances in World Pharma and Biotech Markets is the Report You Need to Stay up to Date in This Exciting Industry

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c92066) has announced the addition of “Strategic Alliances in World Pharma and Biotech Markets” to their offering.

In the last decade or so, strategic alliances and partnerships among pharmaceutical and biotech companies have doubled to around 700 per year per sector, although most of this increase came in the early years. Irrespective of its size, every pharma or biotech company has certain limitations in their own research although usually they have enough capacity in development to bring new compounds to the market very effectively.

However, on a number of occasions, the in-house development capacity may get prioritized in favour of other products within the company’s portfolio. A product may also be facing competition internally from other projects, not necessarily similar compounds, but perhaps programs better aligned to the overall R&D activities. All these make collaboration a viable option, not only to enhance company’s product range, but also its geographic coverage.

For most of these ventures, shareholder value is the ultimate driver, access to new compounds, novel technologies, or IP rights are not the only reasons; however, sharing risks in product development can be just as important a reason for partnering. In addition, even though all big pharma companies have a good selling and marketing capacity (and can always increase it as needed) many alliances are created to optimize the commercialization of products through, for example, detailing to different audiences, marketing with synergistic products or in particular territories where a partner is stronger than the originator.

Recent statistics indicate that all the big pharmaceutical and biotechnology companies have in fact become quite dependent on products deriving from collaborations and on average, 15%-20% of the sales revenue of the top 20 companies comes from licensed products, while around 40% of their pipelines are due to compounds externally sourced.

Contents:

Executive Summary

Introduction to the Synergy between Pharma & Biotech Industries

Overview

Brief History

Thaliomid Predicament - Impact in the Form of Industry Consolidation

Emergence of Genentech and Evolution of Industry-wide Alliances

Introduction to the Biotechnology Industry and Drug Development

Defining Biotechnology

History of Biotechnology

Applications of Biotechnology

What is Drug Development?

Importance of the Development of New Chemical Entity to Drug Development

Cost of the Drug Development Process

Biotechnology and Drug Development – A Symbiotic Relationship

Biotech/Pharma Industries and Network Economics, Competency and Market Structure

Overview

Role of Genomics

Role of Pharma-Biotech Alliances – Present Day Situation

Increasing Collaborative Effort

Executive Summary

Introduction to the Synergy between Pharma & Biotech Industries

Overview

Brief History

Thaliomid Predicament - Impact in the Form of Industry Consolidation

Emergence of Genentech and Evolution of Industry-wide Alliances

Introduction to the Biotechnology Industry and Drug Development

Defining Biotechnology

History of Biotechnology

Applications of Biotechnology

What is Drug Development?

Importance of the Development of New Chemical Entity to Drug Development

Cost of the Drug Development Process

Biotechnology and Drug Development – A Symbiotic Relationship

Biotech/Pharma Industries and Network Economics, Competency and Market Structure

Overview

Role of Genomics

Role of Pharma-Biotech Alliances – Present Day Situation

Increasing Collaborative Efforts in Global Pharma and Biotech Markets

Major Players in the Global Biotech Industry

Major Players in the Global Pharma Industry 38

For more information visit http://www.researchandmarkets.com/reports/c92066